Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

CYTODYN has nominal ( basically no)revenue. Just spiffballing

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
3X Charm Member Profile
 
Followed By 20
Posts 3,004
Boards Moderated 0
Alias Born 03/30/20
160x600 placeholder
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:32:42 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:32:41 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:31:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:30:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:27:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:20:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 5:22:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 4:05:01 PM
CytoDyn reports leronlimab data in NASH trial for first 15 patients Seeking Alpha - 11/24/2021 10:08:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2021 5:24:15 PM
SA Breaking News - PURA estimates $1M in 2022 revenue InvestorsHub NewsWire - 11/22/2021 9:38:18 AM
PURA BULLISH RESURGANCE InvestorsHub NewsWire - 11/19/2021 8:50:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/17/2021 6:02:41 AM
CytoDyn submits the first section of HIV BLA to FDA under rolling review Seeking Alpha - 11/16/2021 7:07:29 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2021 4:55:20 PM
CytoDyn submits leronlimab Breakthrough Therapy designation application to the FDA Seeking Alpha - 11/8/2021 7:50:43 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/5/2021 11:30:49 AM
CytoDyn posts preliminary results from mid-stage leronlimab NASH study Seeking Alpha - 11/3/2021 6:11:13 AM
iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST) InvestorsHub NewsWire - 10/29/2021 2:31:48 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/28/2021 2:06:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2021 1:58:46 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/27/2021 4:27:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/21/2021 4:10:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2021 4:07:39 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/20/2021 5:28:12 PM
3X Charm   Thursday, 11/25/21 06:33:47 PM
Re: crazyjogger925 post# 194797
Post # of 196179 
CYTODYN has nominal ( basically no)revenue. Just spiffballing here, but me thinks a few of the companies cited have products they can sell and generate revenue and have no material value in comparison to Cydy.


Any of those companies desperately discounting shares for immediate sale to keep from going BK?
Doubling down on ludicrous. LMAO!

Besides, it’s not only the number of shares, it is the fact that “cash” is provided by insiders who pay below market for shares and immediately sell them. This adds to the outstanding shares, but also drives the price down because some buyers are getting shares cheaper than others…

If the shares are trading at $1.30 in the market, someone who pays $1.00 can sell at $1.25 and make 25% in a day and get out quick.

Naders insiders do not want to own a piece of this company for more than a minute…they “ are just passing through “ on way to huge profits.

3X

God Bless America!
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences